Profile data is unavailable for this security.
About the company
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
- Revenue in USD (TTM)690.31m
- Net income in USD63.59m
- Incorporated2006
- Employees711.00
- LocationPacira Biosciences Inc5401 West Kennedy Boulevard, Suite 890TAMPA 33609United StatesUSA
- Phone+1 (813) 553-6680
- Fax+1 (302) 655-5049
- Websitehttps://www.pacira.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aquestive Therapeutics Inc | 58.36m | -25.72m | 441.64m | 135.00 | -- | -- | -- | 7.57 | -0.3565 | -0.3565 | 0.7874 | -0.3896 | 0.6685 | 2.85 | 7.25 | 432,296.30 | -29.46 | -76.63 | -42.14 | -123.85 | 68.49 | 64.24 | -44.07 | -102.95 | 6.98 | -2.67 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
Eyepoint Pharmaceuticals Inc | 50.39m | -86.82m | 466.14m | 121.00 | -- | 1.99 | -- | 9.25 | -1.80 | -1.80 | 1.08 | 4.38 | 0.2016 | 1.10 | 8.18 | 416,454.50 | -34.74 | -40.44 | -47.07 | -47.79 | 91.35 | 83.45 | -172.29 | -186.23 | 4.69 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 487.47m | 150.00 | -- | 2.81 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
SIGA Technologies Inc | 172.96m | 83.97m | 491.02m | 45.00 | 5.92 | 2.93 | 5.81 | 2.84 | 1.16 | 1.16 | 2.41 | 2.35 | 1.02 | 0.5866 | 23.09 | 3,843,484.00 | 49.52 | 22.34 | 56.21 | 27.56 | 82.00 | 88.65 | 48.55 | 41.14 | 5.65 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
Emergent Biosolutions Inc | 1.10bn | -587.00m | 496.98m | 1.60k | -- | 1.26 | -- | 0.4509 | -11.24 | -11.24 | 21.13 | 7.30 | 0.597 | 2.39 | 4.53 | 688,875.00 | -31.80 | -2.94 | -49.34 | -3.66 | 27.18 | 53.24 | -53.26 | -5.95 | 0.5438 | -1.87 | 0.6906 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
CorMedix Inc | 806.12k | -53.12m | 512.24m | 82.00 | -- | 10.98 | -- | 635.43 | -0.9262 | -0.9262 | 0.0141 | 0.8355 | 0.014 | -- | -- | 9,830.73 | -92.57 | -54.84 | -110.35 | -62.32 | -64.79 | 6.18 | -6,589.09 | -18,323.42 | 4.43 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
SNDL Inc | 669.74m | -82.92m | 519.55m | 2.52k | -- | 0.5744 | -- | 0.7757 | -0.3174 | -0.3174 | 2.56 | 3.41 | 0.5988 | 4.63 | 33.15 | 266,193.50 | -7.67 | -24.44 | -8.32 | -27.94 | 25.04 | 22.49 | -12.82 | -62.17 | 2.98 | -- | 0.1125 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
Revance Therapeutics Inc | 243.90m | -283.87m | 555.28m | 597.00 | -- | -- | -- | 2.28 | -3.17 | -3.21 | 2.64 | -1.24 | 0.4466 | 1.35 | 9.18 | 408,542.70 | -51.97 | -55.55 | -61.40 | -63.20 | 71.53 | -- | -116.39 | -304.96 | 3.01 | -22.09 | 1.41 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
Avid Bioservices Inc | 142.36m | -144.17m | 668.57m | 371.00 | -- | 11.40 | -- | 4.70 | -2.27 | -2.27 | 2.24 | 0.9192 | 0.3661 | 3.81 | 4.32 | 383,714.30 | -37.08 | -0.826 | -57.59 | -1.20 | 6.27 | 19.26 | -101.27 | -2.14 | 1.05 | -3.18 | 0.7343 | -- | -6.27 | 21.15 | -54,444.79 | -- | 84.15 | -- |
Pliant Therapeutics Inc | 0.00 | -185.41m | 676.11m | 158.00 | -- | 1.71 | -- | -- | -3.09 | -3.09 | 0.00 | 6.50 | 0.00 | -- | -- | 0.00 | -35.03 | -33.24 | -37.15 | -35.39 | -- | -- | -- | -360.29 | -- | -- | 0.0711 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
Pacira Biosciences Inc | 690.31m | 63.59m | 737.57m | 711.00 | 13.67 | 0.8387 | 5.35 | 1.07 | 1.17 | 1.17 | 12.34 | 19.07 | 0.4329 | 1.83 | 6.77 | 970,900.10 | 3.99 | 3.35 | 4.26 | 3.98 | 74.05 | 72.63 | 9.21 | 8.57 | 5.70 | -- | 0.4013 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
Phibro Animal Health Corp | 1.02bn | 2.42m | 846.12m | 1.94k | 350.86 | 3.30 | 21.92 | 0.8314 | 0.0595 | 0.0595 | 25.11 | 6.34 | 1.04 | 2.59 | 6.11 | 524,576.80 | 0.2473 | 3.93 | 0.3071 | 4.90 | 30.82 | 31.18 | 0.2374 | 3.77 | 1.64 | 1.76 | 0.6554 | 56.45 | 4.07 | 4.21 | -92.59 | -46.35 | 6.65 | 0.8548 |
PetIQ Inc | 1.13bn | 13.19m | 930.20m | 1.93k | 81.19 | 3.57 | 16.51 | 0.82 | 0.3802 | 0.3802 | 35.27 | 8.64 | 1.28 | 5.58 | 5.55 | 586,823.10 | 1.54 | -4.32 | 1.96 | -5.23 | 24.63 | 20.05 | 1.21 | -3.66 | 1.68 | 2.09 | 0.63 | -- | 19.58 | 15.83 | 104.42 | -- | 4.96 | -- |
Liquidia Corp | 14.84m | -112.11m | 936.59m | 136.00 | -- | 13.58 | -- | 63.11 | -1.57 | -1.57 | 0.2102 | 0.8208 | 0.0993 | -- | 4.04 | 109,117.60 | -75.00 | -55.02 | -87.85 | -62.69 | 69.52 | 82.18 | -755.46 | -474.59 | 5.78 | -29.47 | 0.578 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 7.10m | 15.25% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 4.98m | 10.71% |
Renaissance Technologies LLCas of 30 Jun 2024 | 2.07m | 4.44% |
Frontier Capital Management Co. LLCas of 31 Mar 2024 | 1.91m | 4.11% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.90m | 4.09% |
Dimensional Fund Advisors LPas of 30 Jun 2024 | 1.75m | 3.76% |
Pacer Advisors, Inc.as of 31 Mar 2024 | 1.57m | 3.38% |
Macquarie Investment Management Business Trustas of 30 Jun 2024 | 1.57m | 3.37% |
Stephens Investment Management Group LLCas of 30 Jun 2024 | 1.37m | 2.95% |
ClearBridge Investments LLCas of 31 Mar 2024 | 1.17m | 2.52% |